Insulin Lispro (Humalog) Market And Forecast, 2025–2033: Strategic Shifts Post-Patent Expiry And Biosimilar Impact

Published: Nov, 2025
Report ID: GVR-MT-100497
Format: PDF/Excel databook

No. of Pages/Datapoints: 120
Report Coverage: 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
  1.2. Segment Definitions
  1.3. Estimates and Forecast Timeline
  1.4. Research Methodology
  1.5. Information Procurement
1.5.1. Purchased Database
  1.5.2. GVR’s Internal Database
  1.5.3. Secondary Sources
  1.5.4. Primary Research
  1.6. Information Analysis
  1.6.1. Data Analysis Models
  1.7. Market Formulation & Data Visualization
  1.8. Model Details
  1.8.1. Commodity Flow Analysis
  1.9. List of Secondary Sources
  1.10. Objectives
Chapter 2. Executive Summary
  2.1. Market Snapshot
  2.2. Segment Snapshot
  2.3. Competitive Landscape Snapshot
Chapter 3. Insulin Lispro (Humalog) Market Variables, Trends, & Scope
  3.1. Market Lineage Outlook
  3.2. Market Dynamics
  3.2.1. Market Driver Analysis
  3.2.2. Market Restraint Analysis
  3.3. Business Environment Analysis
  3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
  3.3.1.2. Buyer Power
  3.3.1.3. Substitution Threat
  3.3.1.4. Threat of New Entrants
  3.3.1.5. Competitive Rivalry
  3.3.2. PESTLE Analysis
  3.3.3. Pipeline Analysis
  3.3.4. Pricing Analysis
Chapter 4. Insulin Lispro (Humalog) Market: Indication Business Analysis
  4.1. Indication Market Share, 2024 & 2033
  4.2. Indication Segment Dashboard
  4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  4.4. Type 1 Diabetes
  4.4.1. Type 1 Diabetes Market, 2021 - 2033 (USD Million)
  4.5. Type 2 Diabetes
  4.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
  4.6. Gestational Diabetes
  4.6.1. Gestational Diabetes Market, 2021 - 2033 (USD Million)
Chapter 5. Insulin Lispro (Humalog) Market: Regional Estimates & Trend Analysis
  5.1. Regional Market Share Analysis, 2024 & 2033
  5.2. Regional Market Dashboard
  5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
  5.4. North America
  5.5. Europe
  5.6. Asia Pacific
  5.7. Latin America
  5.8. Middle East and Africa
Chapter 6. Competitive Landscape
  6.1. Company Profile
  6.1.1. Eli Lilly and Company
  6.1.1.1. Overview
  6.1.1.2. Financial Performance
  6.1.1.3. Strategic Mapping
  6.1.2. Biocon Biologics
  6.1.2.1. Overview
  6.1.2.2. Financial Performance
  6.1.2.3. Product Benchmarking
  6.1.2.4. Strategic Mapping
  6.1.3. Gan & Lee Pharmaceuticals
  6.1.3.1. Overview
  6.1.3.2. Financial Performance
  6.1.3.3. Product Benchmarking
  6.1.3.4. Strategic Mapping
  6.1.4. Geropharm
  6.1.4.1. Overview
  6.1.4.2. Financial Performance
  6.1.4.3. Product Benchmarking
  6.1.4.4. Strategic Mapping
  6.1.5. Novo Nordisk
  6.1.5.1. Overview
  6.1.5.2. Financial Performance
  6.1.5.3. Product Benchmarking
  6.1.5.4. Strategic Mapping
  6.1.6. Sanofi
  6.1.6.1. Overview
  6.1.6.2. Financial Performance
  6.1.6.3. Product Benchmarking
  6.1.6.4. Strategic Mapping
  6.1.7. Boehringer Ingelheim
  6.1.7.1. Overview
  6.1.7.2. Financial Performance
  6.1.7.3. Product Benchmarking
  6.1.7.4. Strategic Mapping

List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Insulin Lispro (Humalog) market, by region, 2021 - 2033 (USD Million)
Table 4 North America Insulin Lispro (Humalog) market, by Indication, 2021 - 2033 (USD Million)
Table 5 Europe Insulin Lispro (Humalog) market, by Indication, 2021 - 2033 (USD Million)
Table 6 Asia Pacific Insulin Lispro (Humalog) market, by Indication, 2021 - 2033 (USD Million)
Table 7 Latin America Insulin Lispro (Humalog) market, by Indication, 2021 - 2033 (USD Million)
Table 8 Middle East & Africa Insulin Lispro (Humalog) market, by Indication, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Insulin Lispro (Humalog) market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Indication outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Insulin Lispro (Humalog) market dynamics
Fig. 12 Insulin Lispro (Humalog) market: Porter’s five forces analysis
Fig. 13 Insulin Lispro (Humalog) market: PESTLE analysis
Fig. 14 Indication market, 2021 - 2033 (USD Million)
Fig. 15 Type 1 Diabetes market, 2021 - 2033 (USD Million)
Fig. 16 Type 2 Diabetes market, 2021 - 2033 (USD Million)
Fig. 17 Gestational Diabetes market, 2021 - 2033 (USD Million)
Fig. 18 Insulin Lispro (Humalog) market revenue, by region
Fig. 19 Regional marketplace: Key takeaways
Fig. 20 North America Insulin Lispro (Humalog) market, 2021 - 2033 (USD Million)
Fig. 21 Europe Insulin Lispro (Humalog) market, 2021 - 2033 (USD Million)
Fig. 22 Asia Pacific Insulin Lispro (Humalog) market, 2021 - 2033 (USD Million)
Fig. 23 Latin America Insulin Lispro (Humalog) market, 2021 - 2033 (USD Million)
Fig. 24 MEA Insulin Lispro (Humalog) market, 2021 - 2033 (USD Million)
Fig. 25 Company categorization
Fig. 26 Company market position analysis
Fig. 27 Strategic framework

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.